Collegium Pharmaceutical (NASDAQ:COLL) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Friday morning,Benzinga reports. They currently have a $50.00 target price on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.80.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $32.91 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a 50-day moving average of $30.57 and a two-hundred day moving average of $34.04. The stock has a market cap of $1.06 billion, a P/E ratio of 14.19 and a beta of 0.82. Collegium Pharmaceutical has a one year low of $28.39 and a one year high of $42.29.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares during the period. TD Private Client Wealth LLC grew its position in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the period. Virtus Fund Advisers LLC purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at about $72,000. Finally, AXA S.A. acquired a new position in Collegium Pharmaceutical in the 2nd quarter worth about $209,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.